ICU patients ≥18 years with expected length of ICU stay ≥2 days are assessed for eligibility (n=15,882)

Excluded due to meeting exclusion criteria (n=11,898)
- 1207 (7.6%) Delirium prior ICU admission
- 1036 (6.5%) Parkinson disease, dementia or alcohol abuse
- 5662 (35.7%) Admitted for acute neurological condition
- 706 (4.4%) Anti-psychotics prior ICU admission
- 673 (4.2%) Prolonged QTc-time/recent history of ventricular tachycardia
- 70 (0.4%) Pregnant or breast feeding
- 496 (3.1%) Reasons that impair delirium assessment
- 284 (1.8%) Moribund
- 1759 (11.1%) Known allergy or intolerance to haloperidol

Informed consent / Deferred consent
- Excluded (n=2188, 13.8%) No informed consent

Randomisation
- Allocated to intervention group (n=353) prophylactic Haloperidol 1mg/q8hr
- Allocated to intervention group (n=734) prophylactic Haloperidol 2mg/q8hr
- Allocated to placebo group (n=709) Sodium chloride 0.9%/ q8hr

Allocation
- No deferred consent (n=3)
- No deferred consent (n=2)
- No deferred consent (n=2)

Follow-up
- Analysed (ITT) (n=350)
- Analysed (ITT) (n=732)
- Analysed (ITT) (n=707)

Intention To Treat
- Analysed (Per Protocol) (n=331)
- Analysed (Per Protocol) (n=682)
- Analysed (Per Protocol) (n=668)